$14.49
+0.00 (+0.00%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+1.33%
1Y
+113.40%
YTD
+1.54%
Open$14.49
Previous Close$14.49
Day High$14.49
Day Low$14.49
52W High$14.50
52W Low$5.93
Volume—
Avg Volume2.89M
Market Cap4.55B
P/E Ratio—
EPS$-0.09
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$13.59
Above
SMA 200
$8.96
Above
RSI (14)
72.2
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Hold
14 analysts
Price Target
+619.5% upside
Current
$14.49
$14.49
Target
$104.26
$104.26
$68.91
$104.26 avg
$125.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 645.81M | 519.01M | 353.38M |
| Net Income | -27,600,660 | -19,963,508 | 71.26M |
| Profit Margin | -4.3% | -4.1% | 20.2% |
| EBITDA | 40.98M | 31.29M | 123.65M |
| Free Cash Flow | — | — | 60.51M |
| Rev Growth | +24.4% | +24.4% | +12.1% |
| Debt/Equity | 1.43 | 1.43 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $244.33 | -0.76% | 122.9 | 446.67B |
| AMGN | Amgen Inc | $403.48 | -1.07% | 26.5 | 206.48B |
| GILD | Gilead Sciences Inc | $129.97 | -1.36% | 17.6 | 161.72B |
| VRTX | Vertex Pharmaceuticals Inc | $484.53 | -0.06% | 27.8 | 120.52B |
| REGN | Regeneron Pharmaceuticals | $767.54 | -0.14% | 17.5 | 77.36B |
| ALNY | Alnylam Pharmaceuticals Inc | $217.83 | -4.76% | 47.7 | 27.52B |